# State of GLP in Japan and Statistical Considerations in the Bioanalytical Guidance

Noriko Katori, PhD National Institute of Health Sciences Shanghai, January 13, 2011



### Topics

- 1. The actual status of GLP in Japan.
- 2. The history of GLP and Analytical Method Validation in Japan.
- 3. Relationship between Japan and Other Countries.
- 4. Statistical considerations for Bioanalytical Guidance.



## The actual status of GLP in Japan




## The Pharmaceutical Affairs Law (Law No. 145)

## Article 43 of Enforcement Regulations of the Pharmaceutical Affairs Law

"The data pursuant to the provisions of the last part of Article 14, Paragraph 3 of the Law shall be collected and complied as specified in the MHW Ordinance on Implementation Standards for Non-Clinical Studies on Safety of Drugs (MHW Ordinance No.21, 1997), ......, MHLW Ordinance on Implementation Standards for Non-Clinical Studies on Safety of Medical Devices (MHLW Ordinance No.36, 2005) ......"

#### Work Flow of Drug / Device Development



### Responsibilities of MHLW and PMDA

#### [MHLW]

Making political agenda and enforcement of administrative actions such as approval, execution of administrative order, etc. based on laws

ex.

- \* Making decision on approval.
- \* Conducting withdrawal and directions of releasing emergent safety information.
- \* Adopting emergent safety measures in significant cases

#### [PMDA]

Review and examination before administrative actions to be taken, implementation of data analysis, etc.

ex.

- \* Review of pharmaceuticals, GMP/GLP/GCP inspections, clinical trial consultations
- Acquisition, examination, analysis, assessment and provision of ADR information





#### **Review Departments**

GLP team
Inspections

Information sharing

GCP team
Inspections







PK, BE

**Document Based Conformity Inspection team** 

Investigations of submitted application dossiers

Office of Conformity Audit



**BMV** 

### Reporting GLP Inspection Results (PMDA)

#### **Inspectors' Findings**

Agreed by both the inspection team and the test facility at the closing meeting



**Inspection Report** 



The GLP Evaluating Committee

(Consisting of External Experts)



**Inspection Result Notification to the Test Facility** 

(by PMDA Chief Executive)

## Areas of Expertise (GLP)

#### For Pharmaceuticals


- ➤ Single Dose toxicity study
- ➤ Repeated Dose toxicity study
- ➤ Reproduction toxicity study
- **≻**Carcinogenicity study
- **≻**Genotoxicity study
- **≻**Local tolerance study
- **≻**Immunotoxicity study
- **≻**Sensitization study
- **≻**Antigenicity study
- **≻**Dependence study
- ➤ Safety Pharmacology
- **≻**Toxicokinetics

#### **Medical Devices specific**

- > Cytotoxicity study
- **≻**Implanted toxicity study
- **▶**Blood compatibility study
- **≻**Pyrogenicity study
- **➤**Biodegradability study



#### Toxicokinetic Study in non-clinical tests and GLP



## The History of GLP and Analytical Method Validation in Japan.



### The History of Guidelines in Japan (GLP / PK/ TK / BE)

Yeare	Japan	Other Countries			
1989-1992	The Guideline for ToxicologyTest (1989) The Guideline for Pharmacokinetic Test (1991)	Shah et al. "Analytical Methods Validation: " Pharm. Res. 9, 588-592 (1992)			
	The Guidance for Toxicokinetics (ICH S3A, 1996)				
	The Guidance for Analytical Validation (ICH Q2A,B, 1997)	OECD principle of GLP (1997, revised)			
	Non clinical test practice standard for drug safety (Ordinance of MHW, 21 <sup>th</sup> , 1997) GLP				
1996-1998	Guideline for Bioequivalence Studies of Generic Products (Q&A, 1998)				
	General Considerations for Clinical Trials (ICH E8, 1998) GCP				
	The Guideline for Non clinical Pharmacokinetic test (1998)				
2001	Clinical Pharmacokinetics of Pharmaceuticals (iyakushin#796, background information for ICH E8)	FDA, Guidance for Industry (Bioanalytical method validation)			
	Symposium for the AAPS/FDA White Papers (MASS2008, Tsukuba, Japan), Dr. Viswanathan was invited.	AAPS/FDA White Paper (2007 - )			
2007-2009	Non clinical test practice standard for drug safety (Ordinance of MHLW, 114 <sup>th</sup> , revised, 2008) GLP	Draft Guideline on Validation of Bioanalytical Methods. EMEA/CHMP/EWP/ 192217/2009 (2009)			
	General procedure of audit for GLPs of pharmaceuticals and medical devices (Ordinance of PMDA, #0815008, 2008)	WHO GCLP (2009, Japanese version, introduced by JQA)			

### ICH Guideline topics and the progress

_	Quality					Safety			Efficacy			Multidisciplinary
	Entre-	Automatic makes	Steamer Sale	(in)	The same	Brown To.	-tue		Daniel Title	Tree:	Personal research	Steamer Steamer
	CHARD	gra.	Justice Transport New Day Substance and Produce	10.4		Next to Community Bollon of Photocopium.			No House of Principles Supress in House Child of Station for Divigo Saturday for Long Street Seasons of of	NO CHARGE A		Modest Statement for Regulatory Assertion
	QUA.		Nation Today Photosophy Trong of Northag Information and Products	158		Toning the Consequentials of Photosoperations	Kita.		Non-1-th Parameter Continue Plant Platts, Pair Management McResses and Passions in Paparland Reprinting Management of the Printing Patrick Trace Wangement	NC-EXTRE		Mariner Residence for the Teacher of Regulation Sections
	dec.	- 4	Statetry Screen, to New Divage Ferror	100,000	-	One felicities for Contemporary States of Photosophical	EDRO	13000	Managara of the Price of Solice Time Management Jos. Solice Date: Execute the Transmission of Solicebook Event Solice Reports.	N(3+C20)		Harrison Common Strike of December (HCTE)
	900	- 3	Bradeing and Marring Broger for Statistic Testing of New Deep Individuals and Resident	non.		Continue on Specific Asperts of Expolates Continues to Text for Pharmacontack	E0080	100.000	Charles To Grand State State	NORO.	14(1/4)	Contact of Section of Edity States for the Visitor of Sense (Texas) From and Medicing Authoritation for Pharmacontrols
	quit		Endonesia el batelto Des	nim .		Community of Reputation States for Terretories: Strong for Photographics	100		Prof. Agency School Plan Management (Schoolsen) and Standards for Expedient Reporting	100.0700		The Common Reduced Department
	iga(#III)	NO. LOS	National Control Number, Named Methodology	101		New For Transaction on Telephones The September of Systems, Engineer or September Studies	KOK.		Plantaurrightou Patring			
	grade.		Seperitor or Ton Drug Substitute	100		Management of National Street Trees	Distr.		Strates and Labor of Chical Study Reports			
	OWNER		Inguestics in New Deep Products	-	704.888	Phonone of Change Street, Street, or Separate	No.	-	Two Respons believes to Superi Ding.	_	_	
				-	-	Autor and Non-Bodye Sough, Comp. Sensitive of Sycology & Republicate St. Wellerant	-	-	THE TAX I WAS A SUPPLY OF SALE	-	-	
	oxae	no bear	Reporter CAMON In Residual Notices	WED.	314.59	Protect & Descrip in Main Facility.	ROBEL .		Dan			
- 23	048		Foliation and Economics of Physics special Sons for the in the R.M. Rigons			Proclated Soldy Transmiss of Remotorings (Survey Places officed) Soldy Wassachige Solds for Massac	er para err		Specifican & Astronomy, Telling Traction in the Acceptability, of Publican Chain.			
	Q48 Asset 1811		Notice of Special Substant Adv Grand Chapter	era.		Phonocolists	man.	in.	(Sort Chesal Partier		_	
	Q49 Asset (97)		Not be Extracted Volume of Resource Experience (Invasial Copie)	erie .		The Time Challed To deploy of the Favority for Technical Institute Experimental (1) Secured Techniques in Secure Photocoxicals	er.		Station in Segment of Special Populations, Complete			
kep S	Q48 Assets (W)		No. to Automotive Communities Sale Trails Supply	un :		Stressertenisty Study, Cr. Spines Physical Physi	to the		Farend Construeron for Chesal Trust			
100	Q40 Asses milit	- 1	Control Control Statement of No. Novil Follows Microbial Conservation Vine Control Chapter	-		Name of Contrast or Advance Personnel	89		Summer Promptor for Chancel From			
- 3	QSR Asses (R)		Promisposius Tor Grand Chapter				N/A		Plane Prised God of Error Person Parish			
	Q48 Asset 683		Smittle Tile Cleaned Chapter				200		PROPERTY OF THE PARTY OF THE PA		-	
	OANED:	1014	Married Statement Statement Works	-	_		F10	No.	Printed Parties of Published of No.	_	-	
		-	Derivat from Gill have of flores or femal Organ Sealout of the Experience Comment is Cally-Coult for						Notice to be a series	-	-	
- 11	Çes		Profession of a PRA Demon Thesis Thomas				-		Probagation and Prostity/deep Prosessal for Non- Assumption of Temporal States and Company (NOSSER) for Company Management (NOSSER)	-	_	
	QAC.		Southing Strong of Management Special Medicagnosis				No.		Plantasi granus. Marina rapresio. Sauses Ban and Sangle Coding Congress.			
	ote		The rate of Charles and Forest Charles									
- 3	iges.		to Product of Brown backgood Brown of Product Comparable of Brown backgood Brown of Product									
- 0		_	Subject to Charges in their Manufacturing Process.	-			_	-		_	-	
- 22	QRA:		for New Drug Rahmanian and New Drug Persturic Planning Statemania									
	quar		Specification: The Principles and Assignment Control									
	of .	NA.	he from backgo of frongs of Products Print March Lang Popular Class St. Nation		_		_	-		_	-	
	OWNER	-	Particulated Specificals Particulated of Confession	-	_		_	-		_	-	
- 10	Ow COR		Maria Sar Manageria Participated Dally Space									
_				-			_	-	Monadash Robard to Ology or Reductionings Product	-	-	
	Q49 Asset 783		Stantator Tor Orand Chapter						Devolupment Colorio, New York and Floring of Qualificative References:			
top: 4	CAR Laure 1981		Table Frieddin, Council Chapter				KOY .		The original falls, Takin Rapid			
	GRE Labour 17		A CONTRACTOR OF THE PARTY OF TH									
-	Quit Court 12	_	PERSONAL PROPERTY.	-		CONTRACT OF THE PROPERTY OF THE PARTY OF THE	_			_	_	
111.12	QCMD.		Imperior Codellar in Rosaled Advance	1081		Interpretative the Pharmacosts, shi femaled the Status.		1 3	Chical Intry Title Management Stee Element for Suscences of Relicited Care Bellin Reports			
up 3	(jalk Assery silt)		Statistically of Eleogy 1 into Economi Chapter	WED.		Action of Solid Transport of Branchistry, Status Processing				N/E		See Streets and September by Daug Harborn
	Q49 Aires (2)		TO THE OWNER OF THE PERSON OF THE PERSON THE									100000000000000000000000000000000000000
	OW hours life.		Read Today to Territory Tages									
ep 2												
THE O	ger.		Notingent at Washing of Day Steamer	108		Particular Transmiss of Photographics						
ep 1	(4)		Superior Contrine for Revokel Miles	-		1 12 - 12 2 - 20				100		The settless Though Voter Bedding and
								_		SWAC TO	_	Married Squares School Street of The

### ICH guideline topic and the progress (Safety)

#### Safety

Status	Code	Previously coded	Document Title
	S1A		Need for Carcinogenicity Studies of Pharmaceuticals
	S1B		Testing for Carcinogenicity of Pharmaceuticals
	S1C(R2)	S1C, S1C(R)	Dose Selection for Carcinogenicity Studies of Pharmaceuticals
	S <sub>2</sub> A		Guidance on Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals
	S2B		Genotoxicity: A Standard Battery for Genotoxicity Testing for Pharmaceuticals
	S <sub>3</sub> A		Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies
c.	S <sub>3</sub> B		Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies
Step 5	S4	S4, S4A	Duration of Chronic Toxicity Testing in Animals (Rodent and Non Rodent Toxicity Testing)
	S5(R2)	S5A, S5B	Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility
	S6		Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
	S7A		Safety Pharmacology Studies for Human Pharmaceuticals
	S7B		The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals
	S8		Immunotoxicity Studies for Human Pharmaceuticals
	S9		Nonclinical Evaluation for Anticancer Pharmaceuticals
Step 4			
Stop 2	S2(R1)		Guidance on Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use
Step 3	S6(R1)		Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals
Step 2			
Step 1	S10		Photosafety Evaluation of Pharmaceuticals

## Guideline for Bioequivalence Studies of Generic Products (Q&A, 1998)

Q-27. What is the specific method for carrying out an analytical validation?

(Answer) It should be needed to do as described below.

#### 1. Pre-analysis validation (development)

- Stability in a matrix (include frozen/thaw cycle)
- \* Trueness (recovery)
- \* Precision (repeatability & intermediate variation)
- Specificity (using matrix coming from multiple individuals)
- Calibration curve
- \* LOD

\* The summary of these validation results should be described in a report.

#### 2. Routine validation

- \* Acceptance criteria for analytical data
- Criteria for reanalysis

\*The results of the routine validation need not be included in a report.

#### 3. References

#### Analytical validation

\* V.P. Shah et al., Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. J. Pharm. Sci., 81, 309 (1992).

#### Acceptance criteria for data

- \* ISO 5725-6 Accuracy (trueness and precision) of measurement methods and results part 6: Use in practice of accuracy values
- **\*** JIS z 8402



## Relationship between Japan and Other Countries



### Relationship between Japan and Other Countries 1 **ICH USA** EU **Japan MRA** (GLP, GCP, GMP) **MAD** GCLP (2009) **OECD WHO**

MRA: Mutual Recognition Agreement

MAD: Mutual Acceptance of Data

GCLP: Good Clinical Laboratory Practice



## Relationship between Japan and Other Countries 2

#### **MAD**

(Mutual Acceptance of Data)

OECD (Countries)
AUS, AU, BE, CAN, CZ, DK,
FIN, FR, GER, GR, HU, ICL, IRE, IT,
JP, KO, LU, MEX,
NL, NO, NZ, PO, PT, SK, SP, SWE,
SWI, TU, UK, USA

Non -members

South Africa 2003

Slovenia 2004

Israel 2005

1981 MAD, 1989 Compliance, 1997 Non-Members

MOU with EC, Switzerland and USA\*

\*Only pesticides program

India, Singapore, Brazil, Argentina (Provisional) China, Russia, Chinese Taipei, Thailand etc.

**Bilateral Cooperation** 

MOU: Memorandum of Understanding

## Statistical Considerations for Bioanalytical Guidance




## Statistical consideration for bioanalytical guidance

- \* Required precision for TK and BE tests.
- \* Error showing non-normal distribution and proper risk estimation.
- \* Origin of errors.
- \* Handling of sadden and unidentified errors.
- \* Bias should be corrected?




### Effect of Analytical Precision on BE Test

#### A. Confidence Interval ≤ 20% (BE test)



#### B. Difference ≤ 20% (point estimate)



consumer's risk producer's risk

Condition for simulation

- Parameter distributes normally
- Number of subjects = 30
- Inter-individual variation = 20%



## Thank you

